This publication reviews the 52-week efficacy findings and pooled safety analysis from the REMIX programme, highlighting durability of response, long-term tolerability, and potential role of remibrutinib in the management of inadequately controlled chronic spontaneous urticaria (CSU).
Independent commentary for the review has been provided by Professor Connie Katelaris, a Senior Staff Specialist in Immunology/Allergy at Campbelltown Hospital and Professor of Immunology/Allergy at Western Sydney University.
Please login below to download this issue (PDF)